MIRA
INFORM REPORT
|
Report Date : |
14.04.2007 |
IDENTIFICATION
DETAILS
|
Name : |
CADILA PHARMACEUTICALS LIMITED |
|
|
|
|
Formerly Known As : |
NOVA BIOTECH PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Cadila Corporate Campus, Sarkhej - Dholka Road, Bhat, Ahmedabad – 382 210, Gujarat, India |
|
|
|
|
Financials (as on) : |
31.03.2005 |
|
|
|
|
Date of Incorporation : |
28.02.1991 |
|
|
|
|
Com. Reg. No.: |
04-15132 |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24231GJ1991PTC015132 |
|
|
|
|
TAN No.: [Tax Deduction
& Collection Account No.] |
AHMC0038ID |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAACC6251E |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer, Seller, Importer and Exporter of Hospital Disposables including Fiberglass casting, Diagnostics, Pharmaceutical Machinery Manufacturers, Animal Health Formulations and Feed Supplements, Agro Business, Plant Tissue Culture, and Bio Fertilizers, Information Technology, Travel Business, Pharmaceutical Products from Basic Chemicals and Bulk Drugs to intermediates and finished formulations. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
RATING
|
STATUS |
PROPOSED
CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable
to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 4500000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established company having fine track. Directors are reported as experienced, respectable and resourceful businessmen. Their trade relations are fair. Payments are usually correct and as per commitments. The company can be considered normal for business dealings at usual trade terms and conditions. |
LOCATIONS
|
Registered Office : |
Cadila Corporate Campus, Sarkhej - Dholka Road, Bhat, Ahmedabad – 382 210, Gujarat |
|
Tel. No.: |
91-79-23825001(15 Lines) |
|
Fax No.: |
91-79-23825039 |
|
E-Mail : |
purchase@cadilapharma.com (For Material Details) branded @cadilapharma.com (For
Product Information) international@cadilapharma.com
(For International Business) website@cadilapharma.com |
|
Area : |
44 acres |
|
Location : |
Owned |
|
|
|
|
Head Office : |
Cadila Corporate Campus, Sarkhej - Dholka Road, Bhat, Ahmedabad – 382 210, Gujarat |
|
Tel. No.: |
91-79-23825001(15 Lines) |
|
Fax No.: |
91-79-23825039 |
|
E-Mail : |
purchase@cadilapharma.com (For Material Details) branded @cadilapharma.com (For
Product Information) international@cadilapharma.com
(For International Business) website@cadilapharma.com |
|
|
|
|
Corporate Office : |
IRMA House, Off C. G. Road, Navrangpura, Ahmedabad - 380 009, Gujarat, India |
|
Tel. No.: |
91-79-26562615 (5 lines) |
|
Fax No.: |
91-79-26425741 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
5000 sq. ft. |
|
Location : |
Owned |
|
|
|
|
Factory 1 : |
Dholka – Manufacturing Plant Survey No. 1389, Trasad Road, Dholka, Ahmedabad – 387 810, Gujarat Tel. No. 91-79-23421841/83/84/3422006/7/8/9/10 Fax No. 91-79-23420315/3421220 Area : 50000 sq. ft. Location : Owned Chemicals SBU – Factory Plot No. 274, GIDC Industrial Estate, Ankleshwar, Gujarat Tel. No. 91-2646-223846 / 252626 / 251519 Fax No. 91-2646-250051 Area : 174557 sq. ft. Location : Owned CHPL – Factory (Associated Company) Survey No. 342, Nani Kadi, Taluka Kadi, District Mehsana, North Gujarat Tel. No. 91-2764-262463 / 242037 / 242194 Fax No. 91-2764-242223 Location : Owned Karnavati Engineering Limited (Associated Company) Survey No. 342, Nani Kadi, Taluka Kadi, District Mehsana, North Gujarat Tel. 91-2764-262463 / 242037 / 242194 Fax. 91-2764-242608 Location : Owned Tissu Culture Lab 756, Prakruti Farm, Hirapur Chowkdi, Hirapur, Ahmedabad, Gujarat Tel. No. 91-79-3855260/3855495/496 Location : Owned IRMA House, Off C. G. Road, Navrangpura, Ahmedabad - 380 009, Gujarat, India Tel. No. 91-79-6562615 (5 lines) Fax. No. 91-79-6425741 Area : 5000 sq. ft. Location : Owned |
DIRECTORS
|
Name : |
Mr. Indravadan Ambalal Modi |
|
Designation : |
Chairman and Managing Director |
|
Address : |
"KAKABA", 13, Sanjay Building, New Sharda Mandir Road, Paldi, Ahmedabad – 380 007, Gujarat |
|
Date of Birth/Age : |
18th February, 1926 |
|
Qualification : |
B. Sc. (Technical), Ph.D. (Biology), Chemical Engineer from USA |
|
Experience : |
50 years |
|
Date of Joining : |
28.02.1991 |
|
Other Directorships:- |
1. Casil Health Products Limited - Chairman 2. Karnavati Engineering Limited – Chairman 3. Indian Research Manifestation Laboratories (Private) Limited (IRM Lab) – Chairman 4. Green Challel Travel Services – Director 5. IRM Investment Private Limited – Trustee 6. IRM Trust |
|
Profile
:- |
He is a Founder Director of the erstwhile Indian Pharmaceutical major company, now restructured as company. He obtained his Bachelor’s degree in Science from the Baroda College in 1948. Thereafter, he specialized in Technology in Pharmaceuticals and Fine Chemicals at the university of Mumbai. As part of its’ Golden Jubilee Celebrations in 1985, University of Mumbai, Department of Chemical Technology, honoured Mr. Modi as its’ Alumni for his excellence of performance in his chosen area. He is revered as th champion of Indian Pharmaceutical Industry attaining its’ present global status. He has been effectively representing the cause of National Pharmaceutical Industry at various for a. As President of Indian Drug Manufacturer’s Association (IDMA) and Chairman of Basic Chemical, Pharmaceuticals and Cosmetics Export Promotion Council (CHEMEXCIL), his contributions are widely acclaimed in the industry circle. He is presented the National Working Group on Patent Laws, India (NWGP) and Indian Drug Manufacturers’ Association (IDMA) on the subject ‘Patent Regime’ proposed in the Uruguay Round at Delhi from September 2-4, 1993. This international conference was jointly sponsored by the Association of Latinoamericana De Industries Pharmaceuticals (ALIFAR, Argentina) and the Canadian Drug Manufacturer’s Association (CDMA, Canada) alongwith NWGPL and IDMA. |
|
|
|
|
Name : |
Dr. Rajiv I. Modi |
|
Designation : |
Managing Director |
|
Address : |
"KAKABA", 13, Sanjay Building, New Sharda Mandir Road, Paldi, Ahmedabad – 380 007, Gujarat |
|
Date of Birth/Age : |
09th May, 1960 |
|
Qualification : |
Ph.
D. in Biological Science
|
|
Other Directorships:- |
· Casil Health Products Limited, Ahmedabad, Gujarat · Karnavati Engineering Limited, Ahmedabad, Gujarat · Tissue Culture Laboratories, Ahmedabad, Gujarat · Green Channel Travel Services Private Limited |
|
Profile
:- |
He has awarded Genetics Society of America’s Best Scientific Poster at the International Genetics Congress held in August 1988 by the Genetics Society of America. Invited participant and speaker at the Gordan Research Microbial Evolution and Population Biology in July 1989 at Plymouth State of College, New Hampshire, USA Presented papers on various aspects of Chemical Engineering, Biochemical Engineering and Biotechnology at Different Institutes in India and abroad. He is being a qualified Biotechnologist has charted out a visionary patha nd company is one of the leading companies making significant investments in the area of Biotechnology. Broadly the areas are Vaccines (Typhoid, Hepatitis ‘B’ Streptokinase etc). Biotherauptics (Hyaluronic Acid), Diagnostics (HIV Kits, Hepatitis ‘C’ diagnostics Kits), PlantTissue Culture (transgenic plants – tomato), Tissure Culture – potato). |
|
|
|
|
Name : |
Mr. Atul Tandon |
|
Designation : |
Director (w.e.f. 04.07.2003) |
|
|
|
|
Name : |
Mr. D. N. Khurana |
|
Designation : |
Director (w.e.f. 04.07.2003) |
|
|
|
|
Name : |
Mrs. Rashmi K. Mankodi |
|
Designation : |
Company Secretary (ACS) |
|
|
|
|
Name : |
Mrs. Shilaben I Modi |
|
Designation : |
Director |
|
|
|
|
Name : |
Mrs. Monika Garware Modi |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Chinubhai R Shah |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Pradip Khandwal |
|
Designation : |
Director |
KEY EXECUTIVES
|
Name : |
Mr. Michael W. Eggleston |
|
Designation : |
Chief Financial Officer / Treasurer of the company |
|
|
|
|
Name : |
Mr. Andrej Gasperlin |
|
Designation : |
Vice President (Pharmaceuticals) |
|
|
|
|
Name : |
Mr. Sherry Newton |
|
Designation : |
Logistics Manager |
|
|
|
|
Name : |
Mr. Juan C. Gonzalez |
|
Designation : |
Vice President (Latin America) |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
|
Names of Shareholders |
No. of Shares |
Percentage of
Holding |
|
|
|
|
|
Mr. Indravadan A. Modi |
848600 |
5.66 |
|
Mr. Rajiv I. Modi |
848600 |
5.66 |
|
Mrs. Shilaben I. Modi |
848600 |
5.66 |
|
I. A. Modi Trust |
5940000 |
39.60 |
|
I. A. Modi – as Partner |
6514200 |
43.42 |
|
Total |
15000000 |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer, Seller, Importer and Exporter of Hospital Disposables including Fiberglass casting, Diagnostics, Pharmaceutical Machinery Manufacturers, Animal Health Formulations and Feed Supplements, Agro Business, Plant Tissue Culture, and Bio Fertilizers, Information Technology, Travel Business, Pharmaceutical Products from Basic Chemicals and Bulk Drugs to intermediates and finished formulations. |
||||||||
|
|
|
||||||||
|
Products : |
Its’ products range includes :- v Cardiovascular Drugs v Gastrointestinal Drugs v Anti Inflammatory/Analgesic Drugs v Antibiotics/Anti Infectives v Vaccines/Immunomodulators v Anti-Diabetic Drugs v Vitamins / Haemantinics v Psychiatric Agents/CNS Drugs v Haemostatics v Antihistamines/Anti Allergic Drugs v Anti-Aids (Anti Retroviral) Therapy v Anti-Cancer (Cytotoxic) Drugs v Ophthalmic Drugs v Veterinary Products v Expectorants/Bronchodilators v Anti-Asthmatic Drugs v Herabal Products |
||||||||
|
|
|
||||||||
|
Brand Names : |
‘ ACILOC’, ‘ENVAS MICOBUTAL’, ‘ CLAX’, ‘ ZASO’, ‘ NODON’, ‘HAEMUP’, ‘LMX’, ‘SYMBIOTEK’, ‘LEPROSY’, ‘RABELOC’, ‘IMMUNO’, ‘MODALATOR’, ‘LEPROVAC’, ‘MONTELAST’. |
||||||||
|
|
|
||||||||
|
Exports to : |
Romania, Russia, Srilanka, Malawi, Kenya, Thailand, Australia, China |
||||||||
|
|
|
||||||||
|
Imports from : |
Europe, Japan, China and U.S.A. |
||||||||
|
|
|
||||||||
|
Terms : |
|
||||||||
|
|
|
||||||||
|
Selling terms : |
L/C, Local Cash and Credit basis |
||||||||
|
|
|
||||||||
|
Purchasing : |
L/C, Local Cash and Credit (180 days) basis |
PRODUCTION STATUS
|
Particulars |
Unit |
Actual Production |
|
Tablets |
ML. Nos. |
3900 |
|
Capsules |
ML. Nos. |
150 |
|
Liquids |
K. litres |
6000 |
|
Sterile Vials |
Millions |
84 |
|
Ampoules |
Millions |
84 |
|
Granules |
Tonnes |
15.06 |
|
Dry Sterile Vials |
Millions |
48 |
|
Dry Syrup Bottles |
Millions |
27 |
GENERAL
INFORMATION
|
Customers : |
§ Buying Agents § Distributors § Clinics § Hospitals § Manufacturers § Retailers § Wholesalers Some of major customer includes: § Apollo Hospital § Sal Hospital § Krishna Heart Hospital § Government Hospitals |
||||||||||||
|
|
|
||||||||||||
|
No. of Employees : |
Around 3800
|
||||||||||||
|
|
|
||||||||||||
|
Bankers : |
Ø Bank of Baroda Ashram Road Branch, Ahmedabad-380 009, Gujarat Ø Corporation Bank Navrangpura Branch, Ahmedabad, Gujarat Ø Oriental Bank of Commerce Ashram Road, Ahmedabad, Gujarat
Ø Punjab National Bank Ashram Road Branch, Ahmedabad – 380 009, Gujarat Ø Union Bank of India Ahmedabad, Gujarat Ø UTI Bank Limited Ahmedabad, Gujarat Ø Syndicate Bank Navrangpura, Ahmedabad, Gujarat
Ø ICICI Bank Bandra, Mumbai, Maharashtra |
||||||||||||
|
|
|
||||||||||||
|
Facilities : |
Oriental Bank of Commerce - The company enjoys hypothecation facility of Rs. 10.000 millions dated 06.04.2000 from its' bankers. UTI Bank Limited - The company enjoys hypothecation facility of Rs. 780.000 millions from its' bankers. Syndicate Bank - The company enjoys hypothecation facility of Rs. 1.400 millions dated 06.04.2000 from its' bankers. ICICI Bank - The company enjoys hypothecation facility of Rs. 300.000 millions dated 06.04.2000 from its' bankers.) |
|
|
|
|
Banking Relations
: |
Good |
|
|
|
|
Auditors : |
Deloitte Haskins and Sells Chartered Accountants |
|
Address: |
3rd Floor, ‘Heritage’, Near Gujarat Vidhyapith, Off Ashram Road, Ahmedabad – 380 014, Gujarat |
|
Tel. No.: |
91-79-7582542/7582543 |
|
Fax No.: |
91-79-7582551 |
|
E-Mail : |
|
|
|
|
|
Associates/Subsidiaries : |
Ø Casil Health Products Limited, Ahmedabad, Gujarat Website: http://www.casilhealth.com Ø Tissue Culture Laboratories, Ahmedabad, Gujarat Ø Green Channel Travel Services Private Limited, Ahmedabad, Gujarat - The Local Agent for American Express Travel Related Services at Ahmedabad Ø Karnavati America Ø CPL Inc., USA Ø Be-Tabs Pharmaceuticals (Pty) Limited Ø CPL – Alliance (South Africa) Ø Cadila (Nigeria) Limited Ø Cadila Pharmaceuticals (E.A.) Limited Ø IRM Investment Private Limited Ø Indian Research Manifestation Laboratories (Private) Limited Ø IRM Trust Ø IRM Labs Limited Ø Karnavati Engineering Limited, Ahmedabad, Gujarat Website: http://www.karnavatiengineering.com Ø Wilnet Communication Private Limited Website: http://www.wilnetonline.net / www.willcall.wilnetonline.net Ø Cadila Overseas Holding Ø Medtek Asia Private Limited Ø Rajshil Investments Private Limited Ø Nova Bio-Tech (India) Limited SUBSIDIARIES
In which subject holds 1,33,000 Ordinary shares of GBP.1 Each
In which subject holds 3,39,587 Ordinary shares of Sri Lankan Rs. 10/- each fully paid up.
16020, Swingley Ridge Road, Suite 145, Chesterfield, MO 63017, USA Tel. (636) 728-1980 Fax. (636) 728-1984 E-mail. contactcpl@cplinc.net Website. http://www.cplinc.net This is wholly owned subsidiary of company located in Ahmedabad, India was incorporated in Missouri in March 1999. The subsidiary’s mission is to provide the North and South American markets with high quality, high value Pharmaceutical products and services. Subject operates through large sized premises for Manufacturing facilities at various locations.
318 Indian Trace, PMB 506, Weston, FL 33327, USA Tel. (954) 217-4914 Fax. (954) 217-4915 E-mail. igonzalez@cplinc.net
|
|
|
|
|
Parent Company |
Ø Cadila Laboratories Limited Promoted by Mr. Indravadan A. Modi and Mr. Ramanbhai B. Patel – Parted in 1996 and formed their group. Viz. Zydus Group – by the Patels and Cadila Pharmaceuticals Group by the Modis. (Subject enjoys approximately Rs. 1 Billion, Term Loan from various Banks and Fis and Cash Credit Limits / Working Capital Loans from Banks Rs. 671.330 millions.) |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
15000000 |
Equity Shares |
Rs. 10/- |
Rs. 150.000
millions |
|
500000 |
6% Redeemable
Preference Shares |
Rs. 100/- |
Rs. 50.000
millions |
|
|
Total |
|
Rs. 300.000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
15000000 |
Equity Shares |
Rs. 10/- |
Rs. 150.000
millions |
|
500000 |
6% Redeemable
Preference Shares |
Rs. 100/- |
Rs. 50.000
millions |
|
|
Total |
|
Rs. 200.000 millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES
OF FUNDS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
|
|
SHAREHOLDERS
FUNDS |
|
|
|
|
|
1] Share Capital |
200.000 |
200.000 |
200.000 |
|
|
2] Share
Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves &
Surplus |
918.440 |
785.500 |
642.813 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
NETWORTH
|
1118.440 |
985.500 |
842.813 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1787.169 |
1919.300 |
1971.395 |
|
|
2] Unsecured
Loans |
39.210 |
142.800 |
147.187 |
|
TOTAL BORROWING
|
1826.379 |
2062.100 |
2118.582 |
|
|
DEFERRED TAX
LIABILITIES |
0.000 |
0.000 |
244.542 |
|
|
|
|
|
|
|
TOTAL
|
3461.690 |
3047.600 |
3205.937 |
|
|
|
|
|
|
|
APPLICATION OF FUNDS
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block]
|
2080.816 |
1893.100 |
1782.255 |
|
Capital work-in-progress
|
0.000 |
0.000 |
157.662 |
|
|
|
|
|
|
|
INVESTMENT
|
116.968 |
115.800 |
115.032 |
|
DEFERREX TAX ASSETS
|
|
|
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS &
ADVANCES
|
|
|
|
|
|
|
Inventories
|
798.240 |
748.300 |
651.601 |
|
|
Sundry Debtors
|
949.850 |
893.200 |
777.474 |
|
|
Cash & Bank Balances
|
58.747 |
28.900 |
90.167 |
|
|
Other Current Assets
|
442.298
|
0.000
|
0.000 |
|
|
Loans & Advances
|
0.000 |
359.800 |
299.267 |
Total Current Assets
|
2249.135
|
2030.200
|
1818.509 |
|
Less :
CURRENT LIABILITIES & PROVISIONS
|
|
|
|
|
|
|
Current Liabilities
|
379.587 |
1020.100 |
710.975 |
|
|
Provisions
|
818.087 |
36.100 |
36.925 |
Total Current Liabilities
|
1197.674
|
1056.200
|
747.900 |
|
Net Current Assets
|
1051.461 |
974.000 |
1070.609 |
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES
|
212.445 |
64.700 |
80.379 |
|
|
|
|
|
|
|
TOTAL
|
3461.690 |
3047.600 |
3205.937 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2005 |
31.03.2004 |
31.03.2003 |
Sales Turnover [including other
income]
|
4213.032 |
4531.300 |
4093.709 |
|
|
|
|
|
Profit/(Loss) Before Tax
|
155.295 |
207.400 |
138.969 |
Provision for Taxation
|
0.000 |
43.200 |
34.649 |
Profit/(Loss) After Tax
|
155.295 |
164.200 |
104.320 |
|
|
|
|
|
Export Value
|
NA |
NA |
668.591 |
|
|
|
|
|
Import Value
|
NA |
NA |
170.105 |
|
|
|
|
|
Total Expenditure
|
4057.737 |
4323.900 |
3950.400 |
KEY RATIOS
|
PARTICULARS |
|
31.03.2005 |
31.03.2004 |
31.03.2003 |
PAT / Total Income
|
(%)
|
3.68
|
3.62 |
2.55 |
|
|
|
|
|
|
Net Profit Margin
(PBT/Sales) |
(%) |
3.68
|
4.57 |
3.39 |
|
|
|
|
|
|
Return on Total Assets
(PBT/Total Assets} |
(%) |
3.49
|
5.13 |
3.58 |
|
|
|
|
|
|
Return on Investment (ROI)
(PBT/Networth) |
|
0.14
|
0.21 |
0.16 |
|
|
|
|
|
|
Debt Equity Ratio
(Total Liability/Networth) |
|
4.16
|
4.16 |
4.69 |
|
|
|
|
|
|
Current Ratio
(Current Asset/Current Liability) |
|
1.87
|
1.92 |
2.43 |
LOCAL AGENCY
FURTHER INFORMATION
HISTORY
Subject was incorporated on 28.02.1991 at Ahmedabad in Gujarat under the name and style of Nova Biostic (India) Private Limited having Company Registration Number 04-15132.
The name was changed to the present style w.e.f.: 20.06. 1995
It became a deemed public liability company w.e.f. : 15.04.1996
Cadila Pharmaceuticals Limited is a multi product, multi Location Company promoted by Dr. Indravadan A. Modi and his son Dr. Rajiv I. Modi both doctorates in Biology and having long years of experience. The company was promoted in the year 1991 and incorporated with Registrar of Companies, Gujarat on 28.02.1991 in the name of Nova Biostic (India) Private Limited at Sr. No. 04-15132. The name was changed to Cadila Pharmaceuticals Private Limited on 26.06.1995 and become public limited company by changing its name to Cadila Pharmaceuticals Limited on 15.04.1996.
In the year 1995, the earstwhile Cadila Chemicals Limited was amalgamated with other Cadila group companies viz. Cadila Laboratories, Cadila Antibiotics, Cadila Exports, Cadila Veterinary etc. Cadila Group restructed and streamlined its Zydus (Patel Group) and Cadila Pharmaceuticals Limited (Modi Group). Cadila Pharmaceuticals Limited belings to Modi Group. It has become one of India’s most respected research based technical savvy Pharmaceutical Company focused on formulations (Human and Veterinary), New Drug Discovery, Active Pharmaceutical Ingredients, Analytical Research, Photochemistry, Biotechnology, Plant Tissue Culture, Bio-Synthetics, Genetic Engineering, Vaccines and entire gamut of True Life Science today.
The company has full fledged Research and Development Complex with most modern equipments at the cost of Rs. 200 millions having 45000 sq. ft. of area and it is recognized by Department of Science and Technology, Government of India, New Delhi having about 150 scientists working round the clock.
Milestones
§
State-of-the-art formulations manufacturing facility, built to the
exacting specifications of USFDA, TGA, MCA & MCC.
§
One of the best R & D set-ups in the country, manned by a 150-strong
scientists' pool.
§
Strong Formulations Development base.
§
A host of 'Biotech' products launched, including many 'Firsts in India'.
§
World's First manufacturer of Immuvac- a unique Immunomodulator.
§
USFDA approvals for Fluoxetine & Ethambutol manufacturing facilities.
§
ISO 9002 approved Bulk Actives (APIs) manufacturing facility, offering
facilities for contract research.
§
Asia's only manufacturer of 'SULFOLANE' (Tetramethylene Sulfone).
§
Significant global presence.
§
Leadership in Domestic Marketing and Distribution Management.
§
Leader in Indian Generics Market.
Diversifications
§
Hospital Disposables including Fiberglass Casting Tape for the first time
in India
§
Diagnostics
§
Laboratory Chemicals
§
Pharmaceutical Machinery Manufacturing
§
Animal Health Formulations & Feed Supplements
§
Agro Business : Plant Tissue Culture and Bio-fertilizers.
§
Information Technology
§
Travel Business
§
Strategic Business Alliances with world-leaders
The company is all set to create
new records, scale greater heights. It has created new world-class production
and R&D facilities, focusing on research, new process innovations leading
to patents, and meeting global standards. The Company always places the common
man at its core – who should be able to access and afford medicines anywhere in
the world. For us at Cadila, this is the only true benchmark of excellence, and
the only thing that really matters.
The company market their vide range of products through 25 C and S Agents, 1900 Wholesalers, 237318 Pharmacies and 1300 field employees.
The company is in trade terms with :-
Ø Aditya Chemicals
Ø Gujarat Microwax Limited
Ø Gujarat Ampouls Limited
Ø Nima Packaging
Ø Vasu Containers
Ø Yagnesh Printing Press
Profile
Pursuant to its corporate
philosophy of striving for continuous improvement and betterment, the Company
has re-located its manufacturing operations at the state-of-the-art plant at
Dholka, located 50 km from Ahmedabad, the commercial capital of Gujarat. Spread
over 44 acres of verdant, picturesque surroundings, amidst lush green lawns and
thick foliage, the new locale is the most envied pharmaceutical installation in
the Asian sub-continent.
Truly unique in every sense of the term, the Plant’s
standards and facilities can match any other, worldwide. Seven ‘zones of
cleanliness’ have been defined and adhered to, as per the 1997 GMP guidelines
of the European Union. Some of the salient features of the design concepts:
·
No wood or asbestos component.
·
Each zone has separate AHUs (Air
Handling Units), dehumidification unit and dust extraction systems.
·
Segregation of every critical
processing activity in each zone, to avoid cross-contamination.
·
Adherence to stringent
specifications of USFDA, MCA(UK), MCC(South Africa) and TGA (Australia).
·
Respective zones, areas and even
uniforms marked with specific colours of the rainbow (‘Indradhanush’ in the
vernacular), to ensure total segregation.
·
Air environment conditioned in
each area with respect to temperature, humidity, filtration, particle counts,
etc.
·
Conformation of each processing
stage with US Federal Standard 209E class of cleanliness; viz. 100, 1,000,
10,000, 100,000 with respect to room air changes, pressure, particle count,
flow direction etc.
·
Duo Pass Reverse Osmosis (RO)
water system, multi-stage distillation plant, self-sanitizing, sanitary SS 31
6L loops water, water for injection with online monitoring of pH, temperature,
conductivity and TOC requirements as per USP XXIV.
·
Zero-discharge Effluent Treatment
Plant constructed using technology from Advent Integrated System, USA.
·
Environment-friendly VAHP
chillers.
·
Rigvent heat extraction devices
and Natural Skylit system in raw material, packing material and finished good
stores.
·
Isolated and dedicated production
facilities for B-Lactum and Cephalosporin dosage forms.
Photochemistry
There has been a growing trend
towards natural medicines and the use of dietary supplements for modern
healthcare, as people throughout the world are becoming increasingly
dissatisfied with the possible side-effects, lack of noticeable long-term
results and high cost associated with allopathic drugs. Herbal products had
provided a more natural and often more effective alternative.
The company uses the ancient Indian medicinal
science of Ayurveda to make herbal formulations with clinically proven
efficacy. The Company has an experienced phytochemistry research team since
1983 and has developed 30 unique herbal products.
A thorough understanding of the
medicinal value of herbs is achieved in order to work on herbal drugs and to
initiate phytochemical research. Formulation is done through the exact process,
as per the ancient science of Ayurveda.
Phytochemistry Department
activities : -
§
Drug development from
natural origin
§
Establishment of
botanical identity of herbs
§
Phytochemical isolation
and identification
§
Screening of herbal
formulations and isolated compounds
§
Coordination of clinical
pharmacology and clinical trials
§
Development and
manufacturing of herbal dietary supplements
§
Analytical Research of
& designation of herbs
The complex also houses its own
full-fledged R&D center, set up at a cost of Rs. 200 millions.
The Plant is equipped with modern
high-speed machines and integrated packaging lines to be cost efficient.
Extensive use of non-fill devices, collators, Brevetti visual inspection
machines, multi-station tablet presses, FFS machines, high speed vial/ampoule
filler/sealers are some of the examples.
The plant—with high capacities and scope for future
expansion—is capable of manufacturing all dosage forms viz. Tablets, Capsules,
Liquid Orals, Dry Syrups, Aseptic Liquid and Solid preparations, Sachets etc.
The Group is engaged in many activities such as formulations, chemicals,
CHPL, engineering, agriculture and telecommunications.
Fixed assets
v Freehold land
v Leasehold land
v Buildings
v Plant & machinery
v Furniture & fixtures
v Office equipments
v Vehicles
Website Details :
CADILA PHARMA TO LAUNCH WORLD'S FIRST RABEPRAZOLE
INTRAVENOUS DOSAGE IN INDIA
The Ahmedabad-based Cadila Pharmaceuticals (CPL) would be launching the first intravenous (IV) dosage form of the anti-ulcerant drug rabeprazole sodium in the world. The company, which introduced the solid dosage of the drug, Rabeloc, for the first time in the country in 2002, has received the DCGI approval to manufacture and market the IV formulation recently.
Rabeprazole sodium, currently the most advanced anti-ulcerant for duodenal ulcers, gastro ulcers and heartburn (gastroesophageal reflux disease -GERD), with the IV dosage form is advised for severe and life threatening ulcer where patient is having upper gastro-intestinal bleeding. The company will be launching the product under the brand name Rabeloc IV shortly in India.
In the gastro segment, Cadila Pharma is currently a leading player with brands such as Aciloc, Lancus, Domperon, Olit, Morsat and others, which enjoy a significant share of the Rs 4450 millions anti-ulcerant market. The company has conducted extensive multicentric clinical trials on rabeprazole at prestigious institutions like AIIMS (All India Institute of Medical Sciences, New Delhi), LTMC (Lokmanya Tilak Medical College, Mumbai), Sion Hospital, Mumbai and V.S. Hospital (Vadilal Sarabhai Hospital), Ahmedabad.
Rabeprazole is an internationally acclaimed molecule, approved by US FDA and WHO under Essential Drugs & Medicine Policy. Currently the drug is available in 21 countries, including US, UK and Japan which is indicated for acid peptic disorders including heartburn (reflux oseophagitis), gastric and duodenal ulcers etc. In the US, rabeprazole is branded as 'Aciphex' and in the rest of the world it is branded as 'Pariet'.
According to company sources, rabeprazole is a blockbuster drug, as compared to the existing anti-ulcerant therapies, in many aspects. It suppresses acid very fast, thereby relieves pain and acidity quickly. Unlike some drugs, which are effective only at day or at night, Rabeloc works in both daytime and nighttime acidity.
As compared to pantaprazole and esomeprazole, which are only approved for heartburn (GERD), Rabeloc is also approved for other disorders including a rare disorder called "Zollinger Ellison Syndrome'. While pantaprazole is approved for short-term therapy (8 weeks therapy), rabeprazole is approved for long-term and short-term therapies and can be safely administered for 52 weeks or more.
CMT REPORT
(Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject are
derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.41.73 |
|
UK Pound |
1 |
Rs.83.11 |
|
Euro |
1 |
Rs.56.50 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
7 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
55 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|